Wellness & Lifestyle

Astute Imaging offers an AI-powered cardiovascular platform designed for healthcare providers and MedTech companies. This comprehensive cloud solution assists with triaging, diagnostics, fully automated surgery planning, treatment, implanted device recommendation, modeling/simulation, and patient follow-up. It integrates with EMR, PACS, and society registries, leveraging patented Finite Element Analysis for arteries and 25 years of real-world vascular data. The platform aims to enhance productivity, improve patient outcomes, increase accuracy, and provide cost-efficient care through longitudinal tracking. For MedTech, it offers a unified platform for surgery planning, pre/post-market regulatory processes, and R&D, leading to enhanced sales team productivity and reduced time-to-market.

Basecamp Research is an AI company dedicated to solving complex challenges in the life sciences sector. The platform leverages artificial intelligence to explore and expand beyond current biological understanding, focusing on the discovery and design of novel proteins. By training its AI models on a proprietary knowledge graph derived from natural biological data, Basecamp Research enables the creation of highly tailored proteins. These custom-designed proteins are intended for specific applications across various industries, including pharmaceuticals, food, and industrial sectors, offering innovative solutions where traditional biological approaches may fall short.

Elix, Inc. is an AI drug discovery company dedicated to "Rethinking Drug Discovery" by applying artificial intelligence to accelerate the process and maximize successful outcomes. The platform provides advanced predictive and generative models specifically designed for medicinal chemistry, offering an intuitive user interface. These AI models are trained on proprietary data from 16 pharmaceutical partners, covering critical aspects such as activity, ADME (absorption, distribution, metabolism, and excretion), and toxicity. Elix specializes in designing novel, non-obvious structures that have been proven effective across multiple drug discovery programs. The company also offers expert consulting and support from experienced PhD scientists, ensuring hands-on onboarding, seamless workflow integration, and ongoing assistance for its clients.

Reesi is an AI-powered platform designed to significantly improve patient access to oncology clinical trials by streamlining the search and recruitment process. It aggregates and structures publicly available trial data, integrating sponsor insights to provide a comprehensive and transparent overview. The platform helps oncologists, clinics, and study centers quickly identify relevant clinical trials, accelerating patient recruitment and access to potentially life-changing treatments. Reesi aims to foster a more connected and efficient ecosystem for clinical research in oncology, ensuring that suitable studies are found in seconds.

MAbSilico offers an AI-based solution for the rapid and efficient discovery of therapeutic antibody candidates. The platform leverages AI-driven docking and affinity prediction to design antibodies that bind to selected epitopes with high affinity and efficacy. It also evaluates inter-molecular and inter-species reactivity to minimize side effects and anticipate pre-clinical development needs. A key feature is the assessment of antibody sequence liabilities, such as post-translational modifications and aggregation motifs, to optimize stability and limit immunogenicity. MAbSilico aims to deliver fully characterized, high-affinity, and epitope-specific humanized antibodies within 21 days, significantly shortening the discovery pipeline and reducing development risks for biotech and pharma companies.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The company has built a next-generation platform that targets complex decisions in R&D, providing life science intelligence. Their philosophy centers on building technology in the service of science, bringing together science and technology teams to push AI and machine learning boundaries. Building on a decade of investment in their knowledge graph and proprietary ontologies, BenevolentAI supports scientists and executives in leveraging cutting-edge AI with confidence and precision in their work.

BenevolentAI, formerly Proximagen, is a leading AI drug discovery platform dedicated to accelerating biopharma research and development. The platform utilizes advanced AI and machine learning to target complex decisions in R&D, providing life science intelligence at users' fingertips. Building on a decade of investment in its knowledge graph and proprietary ontologies, BenevolentAI supports scientists and executives in leveraging cutting-edge AI with confidence and precision. The company's philosophy centers on building technology in the service of science, bringing together unique cross-sections of science and technology teams to push AI and machine learning to new limits in the pursuit of new medicines for hard-to-treat diseases.

AISCIA Informatics offers an AI-powered platform designed to accelerate the discovery of chemicals and materials through the integration of AI, quantum simulations, and advanced data science. The platform, AISCIA Platform™, provides intelligent, scalable, and sustainable solutions that aim to reduce costs, decrease time to market, and improve product performance. Key features include model training and visualization without coding, high-speed predictions for single or batch processing, and smart optimization capabilities for balancing constraints and achieving breakthrough results. AISCIA delivers enterprise-grade AI solutions for various high-impact use cases, including plastic and polymer optimization with EXTRUDAI OPTIMIZER™, oil and gas process control with PetroAI™, battery development with VoltGenius™, concrete formulation with BuildAI™, and solar panel efficiency with SolarSynapse™. They also offer custom solutions for specific industry challenges.

DANNCE.ai provides an AI-powered solution for motor assessment, allowing clinicians to gather clinical-grade motor data from patient phone videos. It is designed to address the care gap in progressive diseases like Parkinson's, enabling continuous monitoring rather than periodic snapshots. Patients can record guided movement exams remotely with a caregiver using any smartphone, and the AI extracts objective motor data such as tremor frequency, gait velocity, and tap rhythm. This HIPAA-compliant tool integrates into existing clinical workflows, offering objective data between visits to inform treatment decisions and detect medication wearing-off patterns. It is peer-reviewed and clinically proven, providing a secure and encrypted way to track motor symptoms.

Axiom Bio offers a cutting-edge solution for drug discovery by building a translational intelligence layer that connects experimental data to human outcomes. The platform leverages AI to accurately predict and understand drug toxicity, aiming to reduce unexpected drug failures. Axiom utilizes a rich dataset of thousands of clinical-stage molecules, profiled across proprietary experiments, to link experimental data with human clinical outcomes. This enables comprehensive clinical risk assessments grounded in AI-powered mechanistic reasoning, revealing a drug’s full risk profile and uncovering mechanisms driving toxicity. The tool helps scientists make better-informed decisions earlier in development, ultimately leading to safer medicines.

MaxisIT Inc. provides comprehensive AI-driven clinical data management and analytics solutions specifically designed for life sciences organizations. Their platform, Maxis AI, automates data management and analytics processes, ensuring higher-quality data and faster insights for clinical trials. Key products include the Clinical Trials Oversight System for real-time visibility, Data Management Workbench for seamless integrations, and Statistical Computing Environment for accelerated research. The platform also features a Clinical Data Repository, Risk-based Quality Management, Smart Optimizer for AI-enabled analytics, and a Metadata Repository. MaxisIT aims to accelerate drug development timelines and revolutionize clinical data management by offering a single source of truth for clinical study information, supporting roles from clinical operations to executive management.

Orbem leverages AI-powered MRI technology to make the invisible visible, offering fast, accurate, and non-invasive imaging solutions for various biological applications. The tool is designed to transform biological datasets into actionable intelligence, serving sectors such as poultry (in-ovo sexing, fertilization status), fruits (detecting internal defects), nuts (identifying deformation, discoloration, dehydration), and health (providing previously unattainable health insights). Orbem's mission is to build a healthier, more sustainable world by reducing waste across the food system and moving health systems towards proactive, preventive check-ups. Its non-destructive technology ensures accurate grading and reduces batch losses, contributing to global food sustainability and improved animal welfare.

OmiCure is an AI-powered platform designed to assist patients and physicians in their fight against cancer by providing personalized knowledge. The OmiCure AI analyzes a tumor's genomics and transcriptomics, comparing them against an extensive knowledge base of therapies and nutriments. This process helps identify the most suitable treatment and diet options for individual cancer patients. The platform generates a detailed report for medical teams, factoring in thousands of cancer drug-gene and nutriment-gene interactions. Developed over 10 years with leading research laboratories, OmiCure aims to keep doctors at the forefront of innovation by delivering actionable, personalized information for solid tumors at all stages.

Sravathi AI Technology Pvt Ltd pioneers AI-driven solutions for complex drug discovery and development challenges, founded in 2020. The platform leverages generative AI, predictive AI, and physics-based models to design novel compounds, identify and validate targets. It allows clients to rapidly narrow down to a few hundred prioritized compounds for chemical synthesis by considering physico-chemical, ADMET, and pharmaco-kinetic properties. This approach significantly reduces uncertainty, time, and costs in the drug discovery process, transforming chemistry with its cost-effective, rule-based, and data-driven AI platform.

Bioneex is the first AI-powered biopharma matchmaking platform designed to connect early-stage drug development companies with strategic biopharma partners and venture capital investors. The platform streamlines the process of finding suitable collaborators for licensing, co-development partnerships, and investment opportunities. By leveraging AI, Bioneex helps drug development companies gain exposure to relevant partners, increasing the likelihood of advancing innovative medicines from discovery to market. It aims to accelerate drug development by fostering crucial connections within the biopharma ecosystem.

Pangaea Data's PALLUX platform leverages AI to find untreated and under-treated patients by mimicking clinicians' manual review processes based on clinical guidelines. This approach helps identify patients with conditions like COPD, CKD, cancer cachexia, lung cancer, ovarian cancer, Crohn's disease, primary biliary cholangitis, and lupus nephritis, who might otherwise be undiagnosed or misdiagnosed. The platform boasts unparalleled accuracy, published to outperform alternative methods, and is scalable for prevalent, rare, and hard-to-diagnose conditions. It features an intuitive, explainable dashboard that integrates into existing EHR systems, ensuring compliance with healthcare regulations and zero disruption to clinical and IT workflows. Pangaea Data aims to close care gaps and improve patient outcomes worldwide.

Variational AI leverages advanced generative AI through its Enki™ platform to revolutionize early-stage drug discovery. Enki™ generates novel, synthesis-ready, lead-like compounds tailored to specific target product profiles, effectively eliminating the need for traditional hit identification and hit-to-lead phases. This allows biopharmaceutical partners to move directly into lead optimization with structures not discoverable by conventional methods. The platform optimizes across more than 50 parameters, including potency, selectivity, ADMET, and synthetic feasibility, for 760 pre-trained drug targets. By designing de novo molecular structures, Variational AI aims to provide better starting points for drug programs, leading to fewer costly iterations, faster timelines, and a higher probability of success.

NEBULA is an innovative AI platform transforming drug discovery by tackling previously "undruggable" targets. Utilizing physics-driven, dataset-free generative AI, NEBULA maps the full conformational landscape of drug targets at ultra-high atomic resolution, revealing cryptic binding pockets and novel allosteric sites. The platform generates entirely new, drug-like molecules, predicts their binding strength with experimental accuracy before synthesis, and screens candidates for non-toxicity, ADME compliance, and synthesizability. This comprehensive approach enables the rapid repurposing of existing compounds and the development of medicines for diseases long considered untreatable, significantly reducing late-stage failures in drug development.

jaide is an AI-powered platform designed to assist doctors, particularly in oncology, by automating clinical documentation and providing advanced prognostic models. The AI clinical assistant helps healthcare providers save up to 4 hours per week on documentation by automating note-taking and generating medical reports. This allows doctors to focus more on patient care. Additionally, jaide develops AI prognostic models to anticipate cancer evolution and improve therapeutic decisions, with current models for prostate and colorectal cancer, and lung cancer in development. The platform emphasizes quick setup, flexibility, secure HDS data storage (GDPR compliant), FHIR data export, EHR integration, and a user-friendly interface with 1-click launch for AI consultations and dictation.

RETFound is an open-source vision foundation model project hosted on GitHub, dedicated to medical AI applications, particularly for retinal image analysis. It provides a series of foundation models, including its namesake RETFound, as well as integrations with DINOv2 and DINOv3 from Meta. The project emphasizes self-supervised learning, having been pre-trained on 1.6 million retinal images, and has demonstrated effectiveness in various disease detection tasks. Key features include its ability to be efficiently adapted to customized tasks and its generalizability for disease detection. The repository offers detailed instructions for environment setup, fine-tuning with pre-trained weights available on HuggingFace, and evaluation procedures, making it a valuable resource for researchers and developers in medical imaging AI.

BioReact is an AI-powered bioprocess optimization platform designed to transform siloed bioprocess data into actionable insights. It offers a comprehensive suite of features for bioprocess scientists, including advanced data visualization with heatmaps to identify key process variables, AI/ML simulations for predicting optimal cell growth and yield conditions before experiments, and statistical analysis tools like PCA and ANOVA to compare experimental outcomes. The platform aims to simplify data management by integrating with various lab equipment such as Sartorius, Infors, and Eppendorf, and supports ELNs. BioReact structures online signals, offline measurements, and experimental metadata, enabling predictive modeling and AI-driven optimization to increase yield and reduce development cycles.

Qureight is a tech-first, AI-powered imaging Contract Research Organization (CRO) dedicated to accelerating the impact of new life-saving therapies for lung and heart disease. The platform delivers its suite of products through a proprietary data and imaging curation system, enabling the analysis of clinical imaging and healthcare data. Qureight offers automated image management and AI analysis in therapeutic areas such as Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Hypertension, and Bronchiectasis. Its offerings include global imaging CRO services, AI-powered endpoints and analytics with proprietary lung image biomarkers (Lung8™, Air8™, Fibr8™, Glass8™, Vascul8™), and data science products leveraging large real-world datasets for synthetic control arms and early drug development support.

AlphaMeld Corporation offers a framework designed to accelerate innovation within the drug discovery and development lifecycle. The platform leverages AI and machine learning to extract critical insights from a wide array of data sets, facilitating the creation of new drug programs. While specific features are not detailed on the publicly accessible pages, the emphasis is on providing a robust system for pharmaceutical and biotech research. The tool aims to streamline complex processes and enhance decision-making in the pursuit of transformative therapies, suggesting a focus on data analysis and program management within the scientific domain.

Arkus AI is a conversational, no-code platform specifically designed for building AI-powered agents within the health, wellness, and life sciences domains. Unlike general-purpose AI tools, Arkus AI provides domain-specific focus, healthcare-specific building blocks, and pre-built templates to accelerate development. It supports various solutions, including medical guideline interpretation, patient consent, symptom tracking, and research synthesis agents. The platform is built with compliance in mind, addressing regulatory, data sensitivity, and domain complexity challenges unique to healthcare. Users can customize agents through conversation, configuration, or code, and data sovereignty is maintained as data doesn't need to reside on the Arkus platform.